EGFR-Targeted Antibodies: Clinical Applications, Treatment Challenges, and Ongoing Scientific Research David Cunningham, MD, FRCP Head, Gastrointestinal and

Cetuximab is a monoclonal antibody to the epidermal growth factor receptor (EGFR) ... Targeted therapies have demonstrated a survival benefit in selected ...

Correlating Response to Anti-EGFR Therapy 6th International Congress on Targeted Therapies in Oncology August 26, 2007 Author: paow Created Date

EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS The HER Family Effects of HER1/EGFR ... to hormonal therapy Poor prognosis Reduced survival HER1/EGFR-Targeted ...

Erb-B1. HER1. EGFR . Erb-B2. HER2. neu . Erb-B3. HER3 . The HER Family of Receptors . Tyrosine. kinase. domain . Ligand-binding. domain . Erb-B4. HER4 . TGF-α. EGF ...

Topics in Oncology New Advances in Targeted Therapy for Colorectal Cancer

Kareptis et. al. 2008, Chang et. al. 2009, Bardelli, Siena 2009 & Siena 2010 . Not everyone with mCRC responds to EGFR targeted therapies . In patients with wild type ...

Jean-Charles Soria Institut Gustave Roussy, Villejuif, France Where are we going next? Molecular-targeted agents for the future Why do we need new treatments for lung ...

Focus on Targeted Therapy TREE 1 Study Design mFOLFOX Oxaliplatin 85 mg/m2 ... drugs 17-20 Molecular Targets in Metastatic Colorectal Cancer Epidermal growth factor receptor ...

Epidermal Growth Factor Receptor (EGFR) Inhibitors Dr.M.Jayanthi EGFR signal transduction in tumour ... Herbst R.S, Fukuoka M, Baselga J. Gefitinib – a novel targeted approach ...

Open clinical issues for the therapeutic use of EGFR-targeted drugs . Appropriate selection of potentially responding patients to EGFR-targeted agents:

... EGFR-targeted therapy: Tarceva® ALK-targeted therapy: Crizotinib clinical trial EGFR ... TS and ALIMTA Challenges EGFR (Epidermal Growth Factor Receptor) and KRAS ...

EGFR is a receptor tyrosine kinase. Mutated --> targeted therapies include monoclonal antibodies against extracellular domain such as cetuximab and matuzumab and TK ...

Prewett M, Rothman M, Waksal H, et al. Mouse-human chimeric anti-epidermal growth factor receptor ... with high affinity and has terminal half life of 2-3 wks Targeted ...

... clearance doubles in smokers Gefitinib limited access only since 2005 Lapatinib approved in 2007 w/ capecitabine erb2 exp adv breast ca * * * * * * EGFR Targeted Therapy ...

COMBINING TARGETED AGENTS Combining -EGFR & -VEGF therapy Jung, YD et al., Eur ... Biological efficacy of a chimeric antibody to the epidermal growth factor receptor ...

Selecting targeted therapies . EGFR TKIs; EGFR FISH and/or mutations; Clinical characteristics (never smoking, Asian) K-ras; Other potential markers need verification

Targeted Drug Development: Wrong Turns and Blind Alleys On The Road to Success ... of Imatinib Mesylate Development of VEGF and RTK Inhibitors Development of EGFR-Is ...

... more toxics than doublets Median survival 8-9 months Targeted Agents Tested in Combination with Chemotherapy Receptor-Targeted Therapy Epidermal Growth Factor Receptor ...

... Clinical Oncology and CAP Guideline Recommendations for Human Epidermal Growth Factor Receptor ... Inhibitors and Their Targets Experimental Her 2 Neu and EGFR Targeted ...